NO965183L - Serotonin 5-HT<N>1A</N>-og dopamin D<N>2</N>-reseptorligander - Google Patents

Serotonin 5-HT<N>1A</N>-og dopamin D<N>2</N>-reseptorligander

Info

Publication number: NO965183L
Authority: NO; Norway
Prior art keywords: alkyl; dopamine; cycloalk; alkenyl; hydrogen
Prior art date: 1994-06-08

Application number

NO965183A

Other languages

English (en)

Other versions

NO965183D0 (no

NO308534B1 (no

Inventor

Jens Kristian Perregaard

Ejner Knud Moltzen

Original Assignee

Lundbeck & Co As H

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

1994-06-08

Filing date

1996-12-04

Publication date

1996-12-04

1996-12-04 Application filed by Lundbeck & Co As H filed Critical Lundbeck & Co As H

1996-12-04 Publication of NO965183D0 publication Critical patent/NO965183D0/no

1996-12-04 Publication of NO965183L publication Critical patent/NO965183L/no

2000-09-25 Publication of NO308534B1 publication Critical patent/NO308534B1/no

Links

QZAYGJVTTNCVMB-UHFFFAOYSA-N serotonin Chemical compound C1=C(O)C=C2C(CCN)=CNC2=C1 QZAYGJVTTNCVMB-UHFFFAOYSA-N 0.000 title abstract 6
229940076279 serotonin Drugs 0.000 title abstract 2
VYFYYTLLBUKUHU-UHFFFAOYSA-N dopamine Chemical compound NCCC1=CC=C(O)C(O)=C1 VYFYYTLLBUKUHU-UHFFFAOYSA-N 0.000 title 2
229960003638 dopamine Drugs 0.000 title 1
239000003446 ligand Substances 0.000 title 1
125000000217 alkyl group Chemical group 0.000 abstract 3
125000003342 alkenyl group Chemical group 0.000 abstract 2
229910052739 hydrogen Inorganic materials 0.000 abstract 2
239000001257 hydrogen Substances 0.000 abstract 2
102000004980 Dopamine D2 Receptors Human genes 0.000 abstract 1
108090001111 Dopamine D2 Receptors Proteins 0.000 abstract 1
VGGSQFUCUMXWEO-UHFFFAOYSA-N Ethene Chemical group C=C VGGSQFUCUMXWEO-UHFFFAOYSA-N 0.000 abstract 1
239000005977 Ethylene Substances 0.000 abstract 1
102000017911 HTR1A Human genes 0.000 abstract 1
101150015707 HTR1A gene Proteins 0.000 abstract 1
UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 abstract 1
208000012902 Nervous system disease Diseases 0.000 abstract 1
208000028017 Psychotic disease Diseases 0.000 abstract 1
125000004450 alkenylene group Chemical group 0.000 abstract 1
125000004390 alkyl sulfonyl group Chemical group 0.000 abstract 1
125000002947 alkylene group Chemical group 0.000 abstract 1
125000000304 alkynyl group Chemical group 0.000 abstract 1
125000004419 alkynylene group Chemical group 0.000 abstract 1
125000003710 aryl alkyl group Chemical group 0.000 abstract 1
125000003118 aryl group Chemical group 0.000 abstract 1
150000001875 compounds Chemical class 0.000 abstract 1
125000001316 cycloalkyl alkyl group Chemical group 0.000 abstract 1
125000000753 cycloalkyl group Chemical group 0.000 abstract 1
125000002993 cycloalkylene group Chemical group 0.000 abstract 1
230000000694 effects Effects 0.000 abstract 1
150000002431 hydrogen Chemical class 0.000 abstract 1
YZTJYBJCZXZGCT-UHFFFAOYSA-N phenylpiperazine Chemical class C1CNCCN1C1=CC=CC=C1 YZTJYBJCZXZGCT-UHFFFAOYSA-N 0.000 abstract 1
QQONPFPTGQHPMA-UHFFFAOYSA-N propylene Chemical group CC=C QQONPFPTGQHPMA-UHFFFAOYSA-N 0.000 abstract 1
208000020016 psychiatric disease Diseases 0.000 abstract 1
230000003236 psychic effect Effects 0.000 abstract 1
125000003003 spiro group Chemical group 0.000 abstract 1
125000001424 substituent group Chemical group 0.000 abstract 1
125000001889 triflyl group Chemical group FC(F)(F)S(*)(=O)=O 0.000 abstract 1

Classifications

- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/20—Hypnotics; Sedatives
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/22—Anxiolytics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/26—Psychostimulants, e.g. nicotine, cocaine
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
- A61P25/32—Alcohol-abuse
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/08—Vasodilators for multiple indications
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D233/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
- C07D233/04—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member
- C07D233/28—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D233/30—Oxygen or sulfur atoms
- C07D233/32—One oxygen atom
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D233/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
- C07D233/04—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member
- C07D233/28—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D233/30—Oxygen or sulfur atoms
- C07D233/32—One oxygen atom
- C07D233/36—One oxygen atom with hydrocarbon radicals, substituted by nitrogen atoms, attached to ring nitrogen atoms

Landscapes

Health & Medical Sciences (AREA)
Organic Chemistry (AREA)
Chemical & Material Sciences (AREA)
Engineering & Computer Science (AREA)
Bioinformatics & Cheminformatics (AREA)
Life Sciences & Earth Sciences (AREA)
Public Health (AREA)
General Chemical & Material Sciences (AREA)
Medicinal Chemistry (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Chemical Kinetics & Catalysis (AREA)
Veterinary Medicine (AREA)
Animal Behavior & Ethology (AREA)
Pharmacology & Pharmacy (AREA)
General Health & Medical Sciences (AREA)
Neurology (AREA)
Neurosurgery (AREA)
Biomedical Technology (AREA)
Psychiatry (AREA)
Heart & Thoracic Surgery (AREA)
Cardiology (AREA)
Addiction (AREA)
Vascular Medicine (AREA)
Anesthesiology (AREA)
Pain & Pain Management (AREA)
Hospice & Palliative Care (AREA)
Urology & Nephrology (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
Hydrogenated Pyridines (AREA)
Ultra Sonic Daignosis Equipment (AREA)
Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Plural Heterocyclic Compounds (AREA)
Peptides Or Proteins (AREA)
Steroid Compounds (AREA)
Preparation Of Compounds By Using Micro-Organisms (AREA)

NO965183A 1994-06-08 1996-12-04 Serotonin 5-HT1A- og dopamin D2-reseptorligander NO308534B1 (no)

Applications Claiming Priority (2)

Application Number	Priority Date	Filing Date	Title
DK65794		1994-06-08
PCT/DK1995/000229 WO1995033729A1 (en)	1994-06-08	1995-06-08	Serotonin 5-ht1a and dopamin d2 receptor ligands

Publications (3)

Publication Number	Publication Date
NO965183D0 NO965183D0 (no)	1996-12-04
NO965183L true NO965183L (no)	1996-12-04
NO308534B1 NO308534B1 (no)	2000-09-25

Family

ID=8096051

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
NO965183A NO308534B1 (no)	1994-06-08	1996-12-04	Serotonin 5-HT1A- og dopamin D2-reseptorligander

Country Status (26)

Country	Link
US (2)	US6514993B1 (no)
EP (1)	EP0770066B1 (no)
JP (1)	JPH10500959A (no)
KR (1)	KR100382812B1 (no)
CN (1)	CN1067057C (no)
AT (1)	ATE193016T1 (no)
AU (1)	AU686400B2 (no)
BR (1)	BR9507930A (no)
CA (1)	CA2192113A1 (no)
CZ (1)	CZ287801B6 (no)
DE (1)	DE69517027T2 (no)
DK (1)	DK0770066T3 (no)
ES (1)	ES2148527T3 (no)
FI (1)	FI964897A7 (no)
GR (1)	GR3034105T3 (no)
HU (1)	HUT76470A (no)
IL (1)	IL114027A (no)
MX (1)	MX9605863A (no)
NO (1)	NO308534B1 (no)
NZ (1)	NZ288180A (no)
PL (1)	PL180847B1 (no)
PT (1)	PT770066E (no)
RU (1)	RU2140920C1 (no)
SK (1)	SK281646B6 (no)
WO (1)	WO1995033729A1 (no)
ZA (1)	ZA954688B (no)

Families Citing this family (20)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US6159990A (en) *	1997-06-18	2000-12-12	Synaptic Pharmaceutical Corporation	Oxazolidinones as α1A receptor antagonists
WO1999065887A1 (en) *	1998-06-15	1999-12-23	American Home Products Corporation	Cycloalkyl-substituted aryl-piperazines, piperidines and tetrahydropyridines as serotonergic agents
US6376494B1 (en)	1998-06-15	2002-04-23	American Home Products Corporation	Cycloalkyl-substituted aryl-piperazines, piperidines and tetrahydropyridines as serotonergic agents
GB9912417D0 (en)	1999-05-28	1999-07-28	Pfizer Ltd	Compounds useful in therapy
USRE46117E1 (en)	1999-12-22	2016-08-23	Teva Pharmaceuticals International Gmbh	Modulators of dopamine neurotransmission
FR2803298A1 (fr) *	1999-12-30	2001-07-06	Adir	Nouvelles urees lineaires ou cycliques, leur procede de preparation et les compositions pharmaceutiques qui les contiennent
UA73981C2 (en)	2000-03-10	2005-10-17	Merck Patent Gmbh	(r)-(-)-2-[5-(4-fluorophenyl)-3-pyridylmethylaminomethyl]-chromane for treatment of extrapyramidal movement disorders (variants), pharmaceutical composition and kit
RU2283648C2 (ru) *	2000-11-14	2006-09-20	Мерк Патент Гмбх	Новое применение комбинированных селективных антагонистов допаминового рецептора d2 и агонистов рецептора 5-нт 1a
PT1408964E (pt)	2001-07-26	2007-05-31	Merck Patent Gmbh	Utilização de 2-5-(4-fluorofenil) -3-piridilmetilaminometil-cromano e de seus sais fisiologicamente aceitáveis.
WO2003074518A1 (en) *	2002-03-06	2003-09-12	Merck Patent Gmbh	Thiazole derivatives and their use d2- and 5-ht1a-receptor ligands
WO2005089380A2 (en)	2004-03-16	2005-09-29	The Regents Of The University Of California	Reducing nephropathy with inhibitors of soluble epoxide hydrolase and epoxyeicosanoids
US20050026844A1 (en)	2003-04-03	2005-02-03	Regents Of The University Of California	Inhibitors for the soluble epoxide hydrolase
US20040253576A1 (en) *	2003-04-04	2004-12-16	The Regents Of The University Of California	Modulating cooperative activity of dopamine D1 and D2 receptors to mitigate substance abuse
JP2008517072A (ja) *	2004-10-20	2008-05-22	ザレジェンツオブザユニバーシティーオブカリフォルニア	可溶性エポキシド加水分解酵素の改良された阻害剤
JP2008521821A (ja) *	2004-11-29	2008-06-26	バーテックスファーマシューティカルズインコーポレイテッド	ムスカリン受容体のモジュレーター
EP1863490A2 (en) *	2005-03-28	2007-12-12	Vertex Pharmaceuticals Incorporated	Muscarinic modulators
SE529246C2 (sv)	2005-10-13	2007-06-12	Neurosearch Sweden Ab	Nya disubstituerade fenyl-piperidiner som modulatorer för dopaminneurotransmission
US8422893B2 (en)	2010-01-21	2013-04-16	Samsung Electronics Co., Ltd	Developer and image forming apparatus including the same
AU2013243461A1 (en)	2012-04-04	2014-11-06	Teva Pharmaceuticals International Gmbh	Pharmaceutical compositions for combination therapy
CN110143947B (zh) *	2019-05-29	2021-10-15	华东师范大学	一种色瑞替尼类似物的制备方法

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US3374237A (en) *	1965-05-21	1968-03-19	American Cyanamid Co	1-phenyl-3-(4-phenyl-1-piperazinoalkyl)-imidazolidinones and imidazolidinethiones
DE2263211A1 (de) *	1972-12-23	1974-07-04	Boehringer Sohn Ingelheim	Neue arylpiperazine und verfahren zu ihrer herstellung
US4035369A (en) *	1975-10-08	1977-07-12	Janssen Pharmaceutica N.V.	1-Benzazolylalkyl-4-substituted-piperidines
US4452798A (en) *	1982-06-22	1984-06-05	Warner-Lambert Company	1-Substituted phenyl-4-alkyl hydantoin piperazine compounds as antihypertensive agents
WO1990006303A1 (en) *	1988-12-02	1990-06-14	Pfizer Inc.	Arylpiperidine derivatives
AU8212491A (en) *	1990-06-29	1992-01-23	Upjohn Company, The	Substituted 1-(alkoxyphenyl)piperazines with cns and antihypertensive activity
IT1251144B (it) *	1991-07-30	1995-05-04	Boehringer Ingelheim Italia	Derivati del benzimidazolone
US5314885A (en) *	1992-09-11	1994-05-24	Mcneilab, Inc.	Cyclic benzylamino, benzylamido, and benzylimido antipsychotic agents
JPH09504272A (ja) *	1993-09-15	1997-04-28	メルクシヤープエンドドームリミテツド	ドーパミンアンタゴニストとしてのイミダゾロン及びオキサゾロン誘導体
US6150367A (en) *	1997-10-20	2000-11-21	Council Of Scientific & Industrial Research	1-[4-arylpiperazin-1-yl]-3-[2-oxopyrrolidin/piperidin-1-yl]propanes and their use in medical treatments

1995
- 1995-06-07 IL IL11402795A patent/IL114027A/xx not_active IP Right Cessation
- 1995-06-07 ZA ZA954688A patent/ZA954688B/xx unknown
- 1995-06-08 AU AU27322/95A patent/AU686400B2/en not_active Ceased
- 1995-06-08 DK DK95922420T patent/DK0770066T3/da active
- 1995-06-08 JP JP8500193A patent/JPH10500959A/ja not_active Withdrawn
- 1995-06-08 NZ NZ288180A patent/NZ288180A/en unknown
- 1995-06-08 WO PCT/DK1995/000229 patent/WO1995033729A1/en not_active Ceased
- 1995-06-08 BR BR9507930A patent/BR9507930A/pt not_active Application Discontinuation
- 1995-06-08 KR KR1019960707006A patent/KR100382812B1/ko not_active Expired - Fee Related
- 1995-06-08 PL PL95317530A patent/PL180847B1/pl not_active IP Right Cessation
- 1995-06-08 CA CA002192113A patent/CA2192113A1/en not_active Abandoned
- 1995-06-08 HU HU9603372A patent/HUT76470A/hu unknown
- 1995-06-08 SK SK1549-96A patent/SK281646B6/sk unknown
- 1995-06-08 EP EP95922420A patent/EP0770066B1/en not_active Expired - Lifetime
- 1995-06-08 ES ES95922420T patent/ES2148527T3/es not_active Expired - Lifetime
- 1995-06-08 CN CN95194369A patent/CN1067057C/zh not_active Expired - Fee Related
- 1995-06-08 AT AT95922420T patent/ATE193016T1/de not_active IP Right Cessation
- 1995-06-08 PT PT95922420T patent/PT770066E/pt unknown
- 1995-06-08 DE DE69517027T patent/DE69517027T2/de not_active Expired - Fee Related
- 1995-06-08 CZ CZ19963589A patent/CZ287801B6/cs not_active IP Right Cessation
- 1995-06-08 RU RU97100172A patent/RU2140920C1/ru not_active IP Right Cessation
1996
- 1996-11-26 MX MX9605863A patent/MX9605863A/es not_active IP Right Cessation
- 1996-12-04 NO NO965183A patent/NO308534B1/no not_active IP Right Cessation
- 1996-12-05 FI FI964897A patent/FI964897A7/fi not_active IP Right Cessation
- 1996-12-09 US US09/424,930 patent/US6514993B1/en not_active Expired - Fee Related
2000
- 2000-08-02 GR GR20000401802T patent/GR3034105T3/el not_active IP Right Cessation
2002
- 2002-12-30 US US10/334,481 patent/US20030120070A1/en not_active Abandoned

Also Published As

Publication number	Publication date
EP0770066A1 (en)	1997-05-02
ATE193016T1 (de)	2000-06-15
CN1154107A (zh)	1997-07-09
DE69517027T2 (de)	2000-12-21
HK1000877A1 (en)	2001-11-02
BR9507930A (pt)	1997-11-18
US6514993B1 (en)	2003-02-04
CA2192113A1 (en)	1995-12-14
IL114027A0 (en)	1995-10-31
ZA954688B (en)	1996-01-29
CN1067057C (zh)	2001-06-13
NO965183D0 (no)	1996-12-04
IL114027A (en)	1999-11-30
CZ358996A3 (en)	1997-05-14
EP0770066B1 (en)	2000-05-17
KR100382812B1 (ko)	2003-08-21
PL317530A1 (en)	1997-04-14
US20030120070A1 (en)	2003-06-26
AU686400B2 (en)	1998-02-05
RU2140920C1 (ru)	1999-11-10
SK154996A3 (en)	1997-08-06
ES2148527T3 (es)	2000-10-16
SK281646B6 (sk)	2001-06-11
JPH10500959A (ja)	1998-01-27
MX9605863A (es)	1998-06-30
AU2732295A (en)	1996-01-04
FI964897A0 (fi)	1996-12-05
NO308534B1 (no)	2000-09-25
NZ288180A (en)	1998-07-28
DE69517027D1 (de)	2000-06-21
WO1995033729A1 (en)	1995-12-14
CZ287801B6 (en)	2001-02-14
FI964897A7 (fi)	1996-12-05
PL180847B1 (pl)	2001-04-30
GR3034105T3 (en)	2000-11-30
HUT76470A (en)	1997-09-29
HU9603372D0 (en)	1997-01-28
PT770066E (pt)	2000-11-30
DK0770066T3 (da)	2000-10-09

Legal Events

Date	Code	Title	Description
2006-01-30	MM1K	Lapsed by not paying the annual fees

Publication	Publication Date	Title
NO965183L (no)	1996-12-04	Serotonin 5-HT<N>1A</N>-og dopamin D<N>2</N>-reseptorligander
PL287961A1 (en)	1991-12-02	Method of obtaining novel tricyclic compounds
AR002986A1 (es)	1998-05-27	Nuevos derivados de piperazina sustituida particularmente utiles como antagonistas de receptores de taquiquinina, composiciones farmaceuticas, usosde dichos derivados y procedimiento de preparacion de los mismos.
NZ301285A (en)	2000-01-28	Heterocyclic neurokinin receptor antagonists, preparation and intermediates thereof
ATE194336T1 (de)	2000-07-15	Morpholin tachykinin rezeptor antagonisten
DE69313866D1 (de)	1997-10-16	Chinoxalinderivate als eaa antagonisten
EA199600007A2 (ru)	1996-10-01	Новые трициклические производные, способ их получения, способы получения оптически активных или рацемических колхицина и тиоколхицина, их аналогов или производных с использованием трициклических соединений и промежуточные продукты синтеза
DE69712325D1 (de)	2002-06-06	Verwendung von 4-phenyl-3,6-dihydro-2h-pyridyl derivaten als nmda rezeptor subtyp blocker
EA200500032A1 (ru)	2005-08-25	Производные ацилоксипирролидина и их применение в качестве лигандов v1b или v1b и v1a рецепторов
HK1000877B (en)	2001-11-02	Serotonin 5-ht1a and dopamin d2 receptor ligands
ATE134191T1 (de)	1996-02-15	N-imidazolylderivate von substituiertem tetrahydrocarbazol und cyclohepta(b>indol
NO980144D0 (no)	1998-01-13	Nye heterocykliske forbindelser for behandling av smerte og anvendelse derav
ES2056025A1 (es)	1994-09-16	Nuevos derivados de indol.
MX9800281A (es)	1998-07-31	Compuestos heterociclicos nuevos para el tratamiento de dolores y uso de los mismos.